DOM-ANAGRELIDE CAPSULE
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
19-05-2017
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE)
Inapatikana kutoka:
DOMINION PHARMACAL
ATC kanuni:
L01XX35
INN (Jina la Kimataifa):
ANAGRELIDE
Kipimo:
0.5MG
Dawa fomu:
CAPSULE
Tungo:
ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE) 0.5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Eneo la matibabu:
PLATELET-REDUCING AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0131875001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2006-06-16
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
DOM-ANAGRELIDE
Anagrelide Capsules, House Standard
0.5 mg
PLATELET-REDUCING AGENT
DOMINION PHARMACAL
6111 Royalmount Avenue, Suite #100
Montréal, Québec
H4P 2T4 DATE OF REVISION:
May 18, 2017
SUBMISSION CONTROL NO.: 205385
_ _
_Dom-ANAGRELIDE Product Monograph _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................................
3
SUMMARY PRODUCT INFORMATION
.....................................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................................
3
CONTRAINDICATIONS
...............................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................................
4
ADVERSE REACTIONS
................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................
10
DOSAGE AND ADMINISTRATION
..........................................................................................................
12
OVERDOSAGE
............................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................................
13
STORAGE AND STABILITY
......................................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................................................
17
PART II: SCIENTIFIC INFORMATION
.................................
Soma hati kamili
